Top

Cardiovascular Diabetology

Published in:

Open Access 01-12-2017 | Review

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

Authors: Marit de Jong, H. Bart van der Worp, Yolanda van der Graaf, Frank L. J. Visseren, Jan Westerink

Published in: Cardiovascular Diabetology | Issue 1/2017

Abstract

Background and aims

Pioglitazone targets multiple pathogenic pathways involved in the development of cardiovascular diseases (CVD). The aim of this systematic review and meta-analysis is to assess the effects of pioglitazone treatment on the secondary prevention of CVD.

Methods

Randomized-controlled trials of pioglitazone in patients with CVD were identified through PubMed, Embase, Cochrane and CINAHL, in a search up to May 2016. Studies were included if pioglitazone was compared with any control (usual care, placebo or active comparator) and if patients were previously diagnosed with CVD. The outcomes of interest included major adverse cardiovascular events (MACE), myocardial infarction (MI), stroke, all-cause mortality and heart failure (HF). All outcomes were compared by pooled risk ratios (RR) with a 95% confidence interval (CI). Pooled estimates were calculated using a random-effects model.

Results

Ten studies reported the effects of pioglitazone on any of the outcomes of interest. Pioglitazone reduced recurrent MACE (RR 0.74, 95% 0.60–0.92; I² = 35), MI (RR 0.77, 95% CI 0.64–0.93; I² = 0%), or stroke (RR 0.81, 95% CI 0.68–0.96; I² = 0%). Pioglitazone did not reduce all-cause mortality (RR 0.94, 95% CI 0.81–1.08; I² = 0%), whereas pioglitazone treatment was associated with an increased risk of HF (RR 1.33, 95% CI 1.14–1.54).

Conclusions

Pioglitazone lowers the risk of recurrent MACE, stroke, or MI in patients with clinical manifest vascular disease. Pioglitazone does not lower the risk for all-cause mortality, and increases the risk for the development of HF.

Available only for authorised users

Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MS. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology. 2006;66:641–6. doi:10.1212/01.wnl.0000201253.93811.f6.CrossRefPubMed

Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–31. doi:10.1056/NEJMoa1506930.CrossRefPubMedPubMedCentral

Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–60. doi:10.1161/CIR.0000000000000350.CrossRefPubMed

WHO. The top 10 causes of death. 2016. http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed 4 May 2016.

Kessler T, Vilne B, Schunkert H. The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease. EMBO Mol Med. 2016;8:688–701. doi:10.15252/emmm.201506174.CrossRefPubMedPubMedCentral

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome an american heart association/national heart, lung, and blood institute scientific statement. Circulation. 2005;112:2735–52. doi:10.1161/CIRCULATIONAHA.105.169404.CrossRefPubMed

Wassink AMJ, Van Der Graaf Y, Olijhoek JK, Visseren FL. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J. 2008;29:213–23. doi:10.1093/eurheartj/ehm582.CrossRefPubMed

Tanaka R, Yamashiro K, Okuma Y, Shimura H, Nakamura S, Ueno Y, et al. Effects of pioglitazone for secondary stroke prevention in patients with impaired glucose tolerance and newly diagnosed diabetes: the J-SPIRIT study. J Atheroscler Thromb. 2015;22:1305–16. doi:10.5551/jat.30007.CrossRefPubMed

Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561–73. doi:10.1001/jama.299.13.1561.CrossRefPubMed

10.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–89. doi:10.1016/S0140-6736(05)67528-9.CrossRefPubMed

11.

Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest. 2004;27:982–91. doi:10.1007/BF03347546.CrossRefPubMed

12.

Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79–82. doi:10.1038/34178.CrossRefPubMed

13.

Corzo C, Griffin PR. Targeting the peroxisome proliferator-activated receptor-γ to counter the inflammatory milieu in obesity. Diabetes Metab J. 2013;37:395–403. doi:10.4093/dmj.2013.37.6.395.CrossRefPubMedPubMedCentral

14.

Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol. 2008;153:636–45. doi:10.1038/sj.bjp.0707452.CrossRefPubMed

15.

Rewers M, Zaccaro D, D’Agostino R, Haffner S, Saad MF, Selby JV, et al. Insulin sensitivity, insulinemia, and coronary artery disease: the insulin resistance atherosclerosis study. Diabetes care. 2004;27:781–7. http://www.ncbi.nlm.nih.gov/pubmed/14988302. Accessed 9 Jul 2016.

16.

Motoki T, Kurobe H, Hirata Y, Nakayama T, Kinoshita H, Rocco KA, et al. PPAR-γ agonist attenuates inflammation in aortic aneurysm patients. Gen Thorac Cardiovasc Surg. 2015;63:565–71. doi:10.1007/s11748-015-0576-1.CrossRefPubMed

17.

Xu W, Bi Y, Sun Z, Li J, Guo L, Yang T, et al. Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study). J Intern Med. 2015;277:137–50. doi:10.1111/joim.12293.CrossRefPubMed

18.

Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784–91. doi:10.1210/jcem.87.6.8567.CrossRefPubMed

19.

Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094–9.CrossRefPubMed

20.

DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–15. doi:10.1056/NEJMoa1010949.CrossRefPubMed

21.

Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013;33:393–9. doi:10.1161/ATVBAHA.112.300346.CrossRefPubMed

22.

Martens FM, Visseren FL, De Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol. 2005;46:773–77821.CrossRefPubMed

23.

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71. doi:10.1056/NEJMoa072761.CrossRefPubMed

24.

The Cochrane Public Health Group Guide for developing a Cochrane protocol. 2011. http://ph.cochrane.org/sites/ph.cochrane.org/files/public/uploads/Guide%20for%20PH%20protocol_Nov%202011_final%20for%20website.pdf. Accessed 3 May 2016.

25.

Quality of reporting of meta-analyses (QUORUM) checklist. 1–2. http://www.biomedcentral.com/content/supplementary/1471-2261-10-24-s1.pdf. Accessed 3 May 2016.

26.

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. http://www.ncbi.nlm.nih.gov/pubmed/22008217. Accessed 9 Jul 2016.

27.

J.P. Higgins, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Tabel 8.5a: The Cochrane Collaboration’s tool for assessing risk of bias. http://handbook.cochrane.org/chapter_8/table_8_5_a_the_cochrane_collaborations_tool_for_assessing.htm. Accessed 4 May 2016.

28.

Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. 9.5.2 Identifying and measuring heterogeneity. http://handbook.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm. Accessed 3 May 2016.

29.

Hong SJ, Choi SC, Cho JY, Joo HJ, Park JH, Yu CW, et al. Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis. Circ J. 2015;79:880–8. doi:10.1253/circj.CJ-14-0964.CrossRefPubMed

30.

Lee HW, Lee HC, Kim BW, Yang MJ, Park JS, Oh JH, et al. Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation. Yonsei Med J. 2013;54:1313–20. doi:10.3349/ymj.2013.54.6.1313.CrossRefPubMedPubMedCentral

31.

Suryadevara S, Ueno M, Tello-Montoliu A, Ferreiro JL, Desai B, Rollini F, et al. Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. Thromb Haemost. 2012;108:930–6. doi:10.1160/TH12-06-0397.CrossRefPubMed

32.

Takagi T, Okura H, Kobayashi Y, Kataoka T, Taguchi H, Toda I, et al. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (prevention of in-stent neointimal proliferation by pioglitazone study). JACC Cardiovasc Interv. 2009;2:524–31. doi:10.1016/j.jcin.2009.04.007.CrossRefPubMed

33.

Kaneda H, Shiono T, Miyashita Y, Takahashi S, Taketani Y, Domae H, et al. Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. Heart. 2009;95:1079–84. doi:10.1136/hrt.2008.162842.CrossRefPubMed

34.

Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2006;29:101–6. doi:10.2337/diacare.29.01.06.dc05-1170.CrossRefPubMed

35.

Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38:865–73. doi:10.1161/01.STR.0000257974.06317.49.CrossRefPubMed

36.

Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J. 2008;155:712–7. doi:10.1016/j.ahj.2007.11.029.CrossRefPubMed

37.

Liu J, Wang LN. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2015. doi:10.1002/14651858.CD010693.pub3.PubMedCentral

38.

Liao H, Saver JL, Wu Y, Chen T, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ. 2017;7:1–13. doi:10.1136/bmjopen-2016-013927.

39.

Lee M, Saver JL, Liao HW, Lin CH, Ovbiagele B. Pioglitazone for secondary stroke prevention. Stroke. 2017;48:388–93. doi:10.1161/STROKEAHA.116.013977.CrossRefPubMed

40.

Varas-Lorenzo C, Margulis AV, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L, et al. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord. 2014;14:129. doi:10.1186/1471-2261-14-129.CrossRefPubMedPubMedCentral

41.

Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus. Am J Cardiovasc Drugs. 2011;11:115–28. doi:10.2165/11587580-000000000-00000.CrossRefPubMed

42.

Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2007;298:1180. doi:10.1001/jama.298.10.1180.CrossRefPubMed

43.

Nitta Y, Tahara N, Tahara A, Honda A, Kodama N, Mizoguchi M, et al. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging. JACC Cardiovasc Imaging. 2013;6:1172–82. doi:10.1016/j.jcmg.2013.09.004.CrossRefPubMed

44.

Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, et al. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J. 2009;73:343–51. http://www.ncbi.nlm.nih.gov/pubmed/19096190.

45.

Christoph M, Herold J, Berg-Holldack A, Rauwolf T, Ziemssen T, Schmeisser A, et al. Effects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial. Heart Vessels. 2015;30:286–95. doi:10.1007/s00380-014-0480-0.CrossRefPubMed

46.

Marx N, Wöhrle J, Nusser T, Walcher D, Rinker A, Hombach V, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled. Double-Blind Trial in Nondiabetic Patients. Circulation. 2005;112:2792–8. doi:10.1161/CIRCULATIONAHA.105.535484.PubMed

47.

Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–63. doi:10.2337/diacare.27.1.256.CrossRefPubMed

48.

Hughes AD, Park C, March K, Coady E, Khir A, Chaturvedi N, et al. A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes. Int J Cardiol. 2013;167:1329–32. doi:10.1016/j.ijcard.2012.03.179.CrossRefPubMed

49.

Ordu S, Ozhan H, Alemdar R, Aydin M, Basar C, Caglar O, et al. Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study. Acta Cardiol. 2010;65:401–6. doi:10.2143/AC.65.4.2053898.PubMed

50.

Terui G, Goto T, Katsuta M, Aoki I, Ito H. Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients. J Cardiol. 2009;54:52–8. doi:10.1016/j.jjcc.2009.03.004.CrossRefPubMed

51.

Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, et al. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovasc Diabetol. 2015;14:83. doi:10.1186/s12933-015-0242-z.CrossRefPubMedPubMedCentral

52.

Clarke GD, Solis-Herrera C, Molina-Wilkins M, Martinez S, Merovci A, Cersosimo E, et al. Pioglitazone improves left ventricular diastolic function in subjects with diabetes. Diabetes care. 2017:dc170078. doi:10.2337/dc17-0078.

53.

Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract. 2007;76:279–89. doi:10.1016/j.diabres.2006.09.010.CrossRefPubMed

54.

Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY, et al. Risk of stroke with thiazolidinediones: a 10-year nationwide population-based cohort study. Cerebrovasc Dis. 2013;36:145–51. doi:10.1159/000353679.CrossRefPubMed

55.

Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314:265–77. doi:10.1001/jama.2015.7996.CrossRefPubMed

56.

Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30:2773–8. doi:10.2337/dc07-0717.CrossRefPubMed

57.

Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016;352:i1541.CrossRefPubMedPubMedCentral

58.

Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone. 2014;68:115–23. doi:10.1016/j.bone.2014.08.010.CrossRefPubMed

59.

Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58:493–504. doi:10.1007/s00125-014-3456-9.CrossRefPubMed

60.

Erdmann E, Song E, Spanheimer R, van Troostenburg de Bruyn A-R, Perez A. Observational follow-up of the PROactive study: a 6-year update. Diabetes Obes Metab. 2014;16:63–74. doi:10.1111/dom.12180.CrossRefPubMed

61.

Highlights of prescribing information. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021073s043s044lbl.pdf. Accessed 15 Sep 2017.

62.

American Diabetes Association. Diabetes care. American Diabetes Association. 2017;40(1). http://care.diabetesjournals.org/content/40/Supplement_1. Accessed 29 Sep 2017.

63.

Ou HT, Chang KC, Li CY, Wu JS. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Cardiovasc Diabetol. 2016;15:41. doi:10.1186/s12933-016-0350-4.CrossRefPubMedPubMedCentral

Title: Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
Authors: Marit de Jong
H. Bart van der Worp
Yolanda van der Graaf
Frank L. J. Visseren
Jan Westerink
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2017
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-017-0617-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Preclinical carotid atherosclerosis in patients with latent autoimmune diabetes in adults (LADA), type 2 diabetes and classical type 1 diabetes

α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study

Glycemia and the cardioprotective effects of insulin pre-conditioning in the isolated rat heart

Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy

Clinical outcomes and glycaemic responses to different aerobic exercise training intensities in type II diabetes: a systematic review and meta-analysis

Association between carotid plaque characteristics and acute cerebral infarction determined by MRI in patients with type 2 diabetes mellitus

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage